Drugs / AZD7789
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04612751 | Feb 2021 → May 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04931654 | Sep 2021 → Dec 2024 overdue | gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04612751 ↗ |
| Route | Intravenous | “AZD7789 administered intravenously (IV)” NCT04931654 ↗ |